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IMPORTANCE REACH is the first phase 3 trial to provide information on hepatocellular cancer
(HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring
system used tomeasure the severity of chronic liver disease. This exploratory analysis
demonstrates the relationship between a potential ramucirumab survival benefit, severity of
liver disease, and baseline α-fetoprotein (αFP).
OBJECTIVE To assess treatment effects and tolerability of ramucirumab by Child-Pugh score
in patients with HCC enrolled in the REACH trial.
DESIGN, SETTINGS, AND PARTICIPANTS Randomized, double-blind, phase 3 trial of
ramucirumab and best supportive care vs placebo and best supportive care as second-line
treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from
154 global sites. Overall, 643 patients were randomized and included in this analysis; 565
patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients
considered class B (Child-Pugh scores 7 and 8).
INTERVENTIONS Ramucirumab (8mg/kg) or placebo intravenously plus best supportive care
every 2 weeks.
MAIN OUTCOMES ANDMEASURES Overall survival (OS), defined as time from randomization
to death from any cause.
RESULTS In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in
this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh
score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P = .06) but no apparent benefit for
patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline αFP levels of
400 ng/mL (to convert ng/mL to μg/L, multiply by 1.0) or more, a ramucirumab OS benefit
was significant for a score of Child-Pugh 5 (HR, 0.61; 95% CI, 0.43-0.87; P = .01) and
Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P = .04), but was not significant for Child-Pugh 7
and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was
consideredmanageable. Regardless of treatment arm, patients with Child-Pugh scores
of 7 and 8 experienced a higher incidence of grade 3 or higher treatment–emergent adverse
events, including ascites and asthenia, and special-interest events, including liver injury
and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6.
CONCLUSIONS AND RELEVANCE In unselected patients, a trend for ramucirumab survival
benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline
αFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for
Child-Pugh scores of 5 and 6. Ramucirumab had amanageable toxic effect profile. These
results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC
with underlying Child-Pugh A cirrhosis and baseline αFP levels of 400 ng/mL or more.
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L iver cancer is the sixth most diagnosed cancer world-wide and the second most common cause of cancerdeath,1 andhepatocellular carcinoma (HCC) represents
themajority of primary liver cancers. Inmajor clinical trials2-11
of patients with advanced or unresectable HCC, targeting of
the vascular endothelial growth factor (VEGF) pathway with
small molecule agents2-7 or biologic agents8-11 has been stud-
ied. Sorafenib, which targets the VEGF pathway, remains the
onlyapprovedsystemic treatmentofHCC,validating thepath-
wayasan important target.2,3Despite 1 recent trial12of themul-
titargeted kinase inhibitor regorafenib reporting a signifi-
cantly improvedoverall survival (OS) in thesecond-linesetting,
multiple other trials have been unable to demonstrate a sur-
vival benefit in both first-line and second-line settings andad-
ditional treatment options for HCC continue to be a highly
unmet need.4-7,11,13-15
The REACH trial11 evaluated the safety and efficacy of
the anti-VEGFR-2 monoclonal antibody ramucirumab in
patients with advanced HCC who had received first-line
sorafenib. In the intention-to-treat (ITT) Child-Pugh class A
population, the OS for patients who received second-line
ramucirumab was not significantly longer than for patients
who received placebo. However, in the prespecified sub-
group of patients with baseline α-fetoprotein (αFP) levels
400 ng/mL (to convert ng/mL to μg/L, multiply by 1.0) or
more, patients who received ramucirumab did achieve sig-
nificantly longer OS compared with those who received pla-
cebo (hazard ratio [HR], 0.67; 95% CI, 0.51-0.90; P = .01).
Chronic liver disease is often present in patients with
HCC and complicates HCC treatment. The Child-Pugh score
is frequently used to select or stratify patients in HCC
trials.16-19 The score uses 5 clinical and laboratory measures
(total bilirubin, serum albumin, prothrombin ratio, ascites,
and hepatic encephalopathy) to generate a total score
between 5 and 15. Patients with scores of 5 or 6 have Child-
Pugh class A disease and are considered to have a relatively
good prognosis regarding chronic liver disease; patients
with scores of 7, 8, or 9 have Child-Pugh class B disease and
have an intermediate prognosis; and patients with scores 10
or greater have Child-Pugh Class C disease and have consid-
erably worse survival outcomes.
In general, patients with HCC with Child-Pugh class A
liver disease are considered ideal candidates for anticancer
therapy. However, patients with Child-Pugh class B or C
liver disease are generally excluded from most HCC trials
because the severity of underlying liver dysfunction poses
challenges to anticancer treatment. Consequently, it is
unclear how best to identify patients with Child-Pugh class
B or C liver disease who may benefit from an anticancer
therapy. Furthermore, most of the data regarding the use-
fulness of the Child-Pugh score in HCC have come from
early in the disease course or in first-line systemic treat-
ment; to our knowledge, no data on any relationship
between Child-Pugh score and treatment outcomes are
available in prospective trials in the second-line setting.
We performed the current exploratory analysis to assess
the treatment effect and tolerability of ramucirumabbyChild-
Pugh score in patientswithHCCenrolled in theREACHstudy.
Thepopulationof all randomizedpatientsbyChild-Pughscore
and the population based on baseline αFP levels and Child-
Pugh score were evaluated.
Methods
Patient Population
REACH11 was a randomized, double-blind, placebo-
controlled phase 3 trial with enrollment in 154 global sites;
patients with HCC Child-Pugh class A and class B liver dis-
ease were randomized (N = 644). In the original protocol,
patients with Child-Pugh B disease were eligible, and the
study was also stratified by Child-Pugh class; based on the
independent data monitoring committee evaluation, the
protocol was amended to exclude patients with Child-Pugh
B disease from future enrollment. The final ITT population
comprised only patients with Child-Pugh Class A disease
(n = 565). For the subgroup of patients with baseline αFP
levels 400 ng/mL or more, OS, progression-free survival
(PFS), and treatment interaction tests were prespecified.
Randomization for the ITT population was stratified by geo-
graphic region and etiology of liver disease. Trial methods
have been described previously.11 In the current exploratory
analysis, patients randomized to REACH were assigned to 3
subgroups based on baseline Child-Pugh score determined
from patient case report forms: Child-Pugh 5, Child-Pugh 6,
and Child-Pugh 7 and 8 scores. Because of limited patient
numbers, patients with a Child-Pugh score of 7 or 8 were
combined into a single subgroup to allow meaningful inter-
pretation of the results. The centers’ review committees
approved the study and all patients provided written
informed consent.
Treatment
Patients received either ramucirumab 8 mg/kg (Eli Lilly and
Company) or placebo intravenously every 2 weeks until dis-
easeprogression, unacceptable toxic effects, orwithdrawal of
consent. All patients received best supportive care.11
Key Points
Question Is there a survival benefit for ramucirumab in the
second-line setting for patients with hepatocellular carcinoma
(HCC) when examined by Child-Pugh score and baseline
α-fetoprotein (αFP) levels?
Findings In unselected patients, a trend for ramucirumab survival
benefit was observed in patients with HCC in the Child-Pugh 5
disease subgroup. For patients with baseline αFP levels 400 ng/mL
ormore, a significant survival benefit for patients treatedwith
ramucirumabwas observed in thosewith Child-Pugh scores
of 5 and 6.
Meaning A potential survival benefit in patients with HCC treated
with ramucirumabwas observed in patients with baseline αFP
levels of 400 ng/mL or more. Studies evaluating the predictive
value of αFP levels in patients with HCC treated with ramucirumab
are warranted.
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Outcomes
Overall survival was defined as the time from randomization
todeath fromanycause, andPFSwasdefinedas the time from
randomization to radiographic progression or death. Tumor
response was assessed by protocol-defined criteria based on
Response Evaluation Criteria in Solid Tumours 1.1; objective
response rate was defined as the proportion of patients who
achievedcomplete responsepluspartial responseas their best
overall response; disease control rate was defined as the pro-
portionof patientswhoachieved complete responsepluspar-
tial response plus stable disease as their best overall re-
sponse. Safety datawere collected continuously until 30days
after the completion of study treatment.
Statistical Methods
Overall survival, PFS, and tumor response rates were ana-
lyzed for eachChild-Pugh score subgroup, includingbothαFP
groups (baseline αFP ≥ 400ng/mLor <400ng/mL). Analyses
were designed to compare treatmentswithin Child-Pugh and
αFPgroups.Overall survival andPFSwere analyzedusing the
Kaplan-Meiermethod. Anunstratified log-rank testwas used
to compare treatment effect, and unstratified Cox regression
modelswereused togenerate theHRs.Objective response rate
and disease control rate were compared between the 2 treat-
ment groups using a Cochran-Mantel-Haenszel test. Adverse
eventsweregradedaccordingtoNationalCancer InstituteCom-
mon Terminology Criteria for Adverse Events version 4.0.
Treatment-emergent adverse event data are presented as fre-
quencies and proportions.
Results
Between November 4, 2010, and April 18, 2013, 644 patients
were randomized, ofwhich 357 patientswith a baseline Child-
Pugh score of 5 (n = 177 ramucirumab; n = 180 placebo), 208
with a baseline Child-Pugh score of 6 (n = 108 ramucirumab;
n = 100 placebo), and 78with a baseline Child-Pugh score of 7
and8(n = 39ramucirumab;n = 39placebo)were identified.One
patient with a baseline Child-Pugh score of 9 was randomized
butwas not included in this exploratory analysis. Baseline pa-
tient and tumor characteristics were generally balanced be-
tween treatment groups byChild-Pugh score (Table 1). A lower
percentage of patientswith aChild-Pugh score of 7 and8had a
performancestatusof0inrelationtotheChild-Pugh5or6popu-
lations inboth the ramucirumabandplaceboarms.Other than
performancestatus,noclear trendswere identified in theother
baseline characteristics comparing patients with Child-Pugh
scores of 5, 6, and Child-Pugh scores of 7 and 8.
Figure1depicts theOScurvesofeachChild-Pughscoresub-
group.IntheITTpopulation,apotential ramucirumabtreatment
OSbenefitwasobserved forpatientswithaChild-Pughscoreof
5 (HR,0.80;95%CI,0.63-1.02;P = .06),butnoapparentbenefit
forpatientswithChild-Pughscoresof6or7and8(HR,0.96;95%
Table 1. Baseline Disease Characteristics by Treatment and Child-Pugh Score for All Randomized Patients
Disease Characteristic
Patients, No. (%)
Ramucirumab Placebo
CP 5
(n = 177)
CP 6
(n = 108)
CP 7 and 8
(n = 39)
CP 5
(n = 180)
CP 6
(n = 100)
CP 7 and 8
(n = 39)
Baseline BCLC score, stage C 155 (87.6) 98 (90.7) 36 (92.3) 161 (89.4) 85 (85.0) 36 (92.3)
Primary tumor present 155 (87.6) 104 (96.3) 39 (100.0) 156 (86.7) 94 (94.0) 39 (100.0)
Metastatic sites, No.
0-2 157 (88.7) 98 (90.7) 34 (87.2) 163 (90.6) 89 (89.0) 31 (79.5)
≥3 20 (11.3) 10 (9.3) 5 (12.8) 17 (9.4) 11 (11.0) 8 (20.5)
Etiology of liver disease
Hepatitis B 81 (45.8) 31 (28.7) 15 (38.5) 75 (41.7) 33 (33.0) 15 (38.5)
Hepatitis C 43 (24.3) 40 (37.0) 12 (30.8) 42 (23.3) 33 (33.0) 12 (30.8)
Significant alcohol use 30 (16.9) 29 (26.9) 12 (30.8) 34 (18.9) 27 (27.0) 10 (25.6)
Steatohepatitis (NASH, fatty liver) 14 (7.9) 6 (5.6) 0 (0.0) 10 (5.6) 9 (9.0) 4 (10.3)
Macrovascular invasion present 43 (24.3) 42 (38.9) 13 (33.3) 45 (25.0) 34 (34.0) 16 (41.0)
Extrahepatic spread present 134 (75.7) 75 (69.4) 29 (74.4) 134 (74.4) 65 (65.0) 26 (66.7)
Age 65 y 83 (46.9) 50 (46.3) 21 (53.8) 79 (43.9) 42 (42.0) 15 (38.5)
ECOG PS 0 112 (63.3) 46 (42.6) 11 (28.2) 107 (59.4) 47 (47.0) 15 (38.5)
Reason for discontinuation of sorafenib
Progressive disease 156 (88.1) 92 (85.2) 32 (82.1) 154 (85.6) 85 (85.0) 34 (87.2)
Toxic effects 21 (11.9) 16 (14.8) 7 (17.9) 26 (14.4) 15 (15.0) 5 (12.8)
α-Fetoprotein
<400 ng/mL 107 (60.5) 54 (50.0) 15 (38.5) 96 (53.3) 52 (52.0) 20 (51.3)
≥400 ng/mL 68 (38.4) 52 (48.1) 23 (59.0) 83 (46.1) 48 (48.0) 16 (41.0)
Missing 2 (1.1) 2 (1.9) 1 (2.6) 1 (0.6) 0 3 (7.7)
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CP, Child-Pugh score; ECOG PS, Eastern Cooperative Oncology Group performance status; NASH, nonalcoholic
steatohepatitis.
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CI, 0.71-1.28;P = .76 andHR, 1.00; 95%CI, 0.62-1.60;P = >.99,
respectively).ThePFSHRswere0.59(95%CI,0.47-0.74;P < .001)
forpatientswithaChild-Pughscoreof5;0.78(95%CI,0.58-1.04;
P = .09) forpatientswithaChild-Pughscoreof6;and0.74 (95%
CI,0.46-1.19;P = .22) forpatientswithChild-Pughscoresof7and
8 (eFigure 1 in the Supplement).
In patients with baseline αFP levels 400 ng/mL or more
(n = 290),OSwas favorable forChild-Pughscoresof5 (HR,0.61;
95% CI, 0.43-0.87; P = .01) and Child-Pugh scores of 6 (HR,
0.64; 95% CI, 0.42-0.98; P = .04) (Figure 2). The PFS was fa-
vorable forpatientswithaChild-Pughscoreof5 (HR,0.66;95%
CI, 0.47-0.93; P = .02) (eFigure 2 in the Supplement). In
Figure 1. Overall Survival for All Randomized Patients
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Kaplan-Meier curves show overall
survival for all randomized patients in
the (A) Child-Pugh score 5 subgroup,
(B) Child-Pugh score 6 subgroup, and
(C) Child-Pugh score 7 and 8
subgroup.
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patientswithbaselineαFPlevels less than400ng/mL(n = 344),
no apparent OS improvement was observed in any Child-
Pugh subgroup, and improvement in PFSwas observed in the
Child-Pugh 5 subgroup (eFigures 3 and 4 in the Supplement).
Improvement in objective response rate with ramu-
cirumab treatmentwas observed in patientswith Child-Pugh
scores of 5 or 6, although thiswas not significant in the Child-
Pugh 6 subgroup (Table 2). Significant improvement of
Figure 2. Overall Survival for PatientsWith Baseline α-Fetoprotein Levels 400 ng/mL orMore
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Kaplan-Meier curves show overall
survival for patients with baseline
α-fetoprotein levels 400 ng/mL or
more in the (A) Child-Pugh score 5
subgroup, (B) Child-Pugh score 6
subgroup, and (C) Child-Pugh score 7
and 8 subgroup. To convert ng/mL
to μg/L, multiply by 1.0.
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disease control rate was observed in patients with Child-
Pugh scores of 5 and scores of 7 and 8.
The most frequent treatment–emergent adverse events
(TEAEs)ofanygrade thatwerehigheronthe ramucirumabarm
includedperipheral edema,headache, andhypertension in the
Child-Pugh 5 subgroup (n = 350), and peripheral edema,
ascites, and decreased appetite in the Child-Pugh 6 subgroup
(n = 203) (Table 3). The most frequent adverse events of
special interest (AESI)of anygrade in theChild-Pugh5or6sub-
groups thatwerehigherontheramucirumabarmincluded liver
injuryand/or failure, bleeding, andhypertension (eTable in the
Supplement). Hypertension was the only grade 3 or higher
Table 2. Tumor Response by Child-Pugh Score for All Randomized Patients
Tumor Response
No. (%)
P Value
Child-Pugh 5
P Value
Child-Pugh 6
P Value
Child-Pugh 7 and 8
Ramucirumab
(n = 177)
Placebo
(n = 180)
Ramucirumab
(n = 108)
Placebo
(n = 100)
Ramucirumab
(n = 39)
Placebo
(n = 39)
Objective responsea 15 (8.5) 1 (0.6) <.001 6 (5.6) 1 (1.0) .09 0 1 (2.6) .41
Disease control rateb 110 (62.1) 83 (46.1) .001 51 (47.2) 45 (45.0) .87 19 (48.7) 11 (28.2) .04
Complete response 1 (0.6) 0 NA 0 0 NA 0 0 NA
Partial response 14 (7.9) 1 (0.6) NA 6 (5.6) 1 (1.0) NA 0 1 (2.6) NA
Stable disease 95 (53.7) 82 (45.6) NA 45 (41.7) 44 (44.0) NA 19 (48.7) 10 (25.6) NA
Progressive disease 57 (32.2) 87 (48.3) NA 40 (37.0) 43 (43.0) NA 12 (30.8) 19 (48.7) NA
Not evaluable 10 (5.6) 10 (5.6) NA 17 (15.7) 12 (12.0) NA 8 (20.5) 9 (23.1) NA
Abbreviation: NA, not applicable.
a Objective response includes patients who experienced either complete response or partial response.
bDisease control rate includes patients who experienced complete response, partial response, or had stable disease.
Table 3. Treatment–Emergent Adverse Events Reported in Patients in Ramucirumab Arm by Treatment and Child-Pugh Score
for the Safety Population
Adverse Event
No. (%)
Any Gradea Grade ≥3
Ramucirumab Placebo Ramucirumab Placebo
CP 5
(n = 173)
CP 6
(n = 106)
CP 7
and 8
(n = 38)
CP 5
(n = 177)
CP 6
(n = 97)
CP 7
and 8
(n = 38)
CP 5
(n = 173)
CP 6
(n = 106)
CP 7
and 8
(n = 38)
CP 5
(n = 177)
CP 6
(n = 97)
CP 7
and 8
(n = 38)
Patients with
any TEAE
168 (97.1) 104 (98.1) 38 (100) 165 (93.2) 93 (95.9) 37 (97.4) 102 (59.0) 68 (64.2) 35 (92.1) 73 (41.2) 56 (57.7) 24 (63.2)
Edema
peripheral
56 (32.4) 49 (46.2) 13 (34.2) 23 (13.0) 26 (26.8) 7 (18.4) 0 1 (0.9) 0 0 1 (1.0) 0
Fatigue 42 (24.3) 23 (21.7) 9 (23.7) 39 (22.0) 18 (18.6) 5 (13.2) 3 (1.7) 4 (3.8) 2 (5.3) 4 (2.3) 4 (4.1) 0
Headache 39 (22.5) 15 (14.2) 1 (2.6) 10 (5.6) 5 (5.2) 1 (2.6) 2 (1.2) 0 0 0 0 0
Hypertension 39 (22.5) 16 (15.1) 4 (10.5) 14 (7.9) 7 (7.2) 1 (2.6) 28 (16.2) 6 (5.7) 1 (2.6) 6 (3.4) 4 (4.1) 1 (2.6)
Decreased
appetite
36 (20.8) 28 (26.4) 15 (39.5) 33 (18.6) 16 (16.5) 5 (13.2) 3 (1.7) 3 (2.8) 2 (5.3) 2 (1.1) 0 0
Nausea 36 (20.8) 18 (17.0) 14 (36.8) 34 (19.2) 18 (18.6) 8 (21.1) 0 0 0 0 0 0
Abdominal pain 32 (18.5) 18 (17.0) 5 (13.2) 39 (22.0) 22 (22.7) 7 (18.4) 5 (2.9) 0 2 (5.3) 5 (2.8) 7 (7.2) 1 (2.6)
Ascites 31 (17.9) 45 (42.5) 10 (26.3) 17 (9.6) 21 (21.6) 10 (26.3) 6 (3.5) 7 (6.6) 6 (15.8) 6 (3.4) 4 (4.1) 7 (18.4)
Diarrhea 31 (17.9) 24 (22.6) 6 (15.8) 25 (14.1) 13 (13.4) 7 (18.4) 1 (0.6) 2 (1.9) 0 1 (0.6) 1 (1.0) 1 (2.6)
Proteinuria 31 (17.9) 14 (13.2) 0 7 (4.0) 6 (6.2) 1 (2.6) 4 (2.3) 2 (1.9) 0 0 0 0
Asthenia 29 (16.8) 20 (18.9) 12 (31.6) 18 (10.2) 17 (17.5) 5 (13.2) 10 (5.8) 4 (3.8) 4 (10.5) 2 (1.1) 3 (3.1) 2 (5.3)
Cough 29 (16.8) 14 (13.2) 4 (10.5) 18 (10.2) 5 (5.2) 6 (15.8) 1 (0.6) 0 0 0 0 0
Thrombocytopenia 28 (16.2) 22 (20.8) 6 (15.8) 8 (4.5) 4 (4.1) 2 (5.3) 8 (4.6) 5 (4.7) 2 (5.3) 0 1 (1.0) 0
Epistaxis 24 (13.9) 15 (14.2) 11 (28.9) 11 (6.2) 6 (6.2) 6 (15.8) 0 0 0 0 0 0
Pyrexia 24 (13.9) 23 (21.7) 7 (18.4) 11 (6.2) 15 (15.5) 7 (18.4) 1 (0.6) 0 0 1 (0.6) 0 0
Constipation 23 (13.3) 15 (14.2) 1 (2.6) 22 (12.4) 12 (12.4) 4 (10.5) 0 0 0 0 0 0
Abdominal pain
upper
21 (12.1) 6 (5.7) 4 (10.5) 13 (7.3) 11 (11.3) 6 (15.8) 1 (0.6) 1 (0.9) 0 0 1 (1.0) 0
Vomiting 21 (12.1) 11 (10.4) 9 (23.7) 22 (12.4) 16 (16.5) 4 (10.5) 2 (1.2) 0 0 0 2 (2.1) 0
Pruritus 20 (11.6) 8 (7.5) 7 (18.4) 18 (10.2) 11 (11.3) 5 (13.2) 0 0 0 0 1 (1.0) 0
Rash 18 (10.4) 6 (5.7) 3 (7.9) 5 (2.8) 7 (7.2) 1 (2.6) 0 0 0 0 0 0
Abbreviations: CP, Child-Pugh score; TEAE, treatment–emergent adverse events.
a Included are any-grade treatment-emergent adverse events that occurred in10% of ramucirumab patients with a Child-Pugh 5 score.
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TEAE and/or AESI observed in 10% ormore of patients in the
ramucirumab arm and higher than placebo (>5% difference).
Overall, the safety profile of ramucirumabwasmanageable in
the Child-Pugh 5 and 6 subgroups.
For theChild-Pugh7and8subgroup (n = 76), themost fre-
quent TEAEs of any grade that were higher in the ramu-
cirumab arm included decreased appetite, nausea, asthenia,
and peripheral edema (Table 3). The most frequent AESIs of
any grade that were higher in the ramucirumab arm included
liver injury and/or failure, hypertension, and infusion-
related reactions (eTable in the Supplement). The incidence
of any-grade liver injury and/or failure AESIs, including clini-
cal and laboratory events,washigher in the ramucirumabarm
(81.6%) compared with the placebo arm (55.3%). However,
when adjusted for duration of exposure to study treatment,
therewasnodifference between treatment arms in theChild-
Pugh 7 and8 subgroup (incidence rates per 100patient years:
326.1 [ramucirumab] vs 321.5 [placebo]). Hepatic encepha-
lopathy andasthenia in theChild-Pugh7and8 subgroupwere
theonlygrade3orhigherTEAEsand/orAESIsobserved in 10%
or more of patients in the ramucirumab arm and higher than
placebo (>5% difference); the number of patients who expe-
rienced encephalopathy was low (n = 4), and no grade 5 in-
stances were reported for either event.
In general, regardless of treatment arm, patients with a
Child-Pugh score of 7 and 8 appeared to experience a higher
incidence of grade 3 or higher TEAEs or AESIs comparedwith
patientswithaChild-Pugh5orChild-Pugh6score. In theChild-
Pugh 7 and 8 subgroup comparedwith Child-Pugh 5 or Child-
Pugh 6 subgroups, the only specific grade 3 or higher TEAEs
that appearedhigher in both treatment armswere ascites and
asthenia. Patients with Child-Pugh scores of 7 and 8 also ap-
peared toexperienceahigher incidenceof thegrade3orhigher
AESIs of liver injury and/or failure and bleeding and/or hem-
orrhage comparedwith patientswith aChild-Pugh 5or Child-
Pugh6score.Regardlessof treatmentarm,ahigher rateofsome
adverse events in patientswith higher Child-Pugh scoreswas
observed, consistent with adverse events that might be ex-
pected in patients with more severe liver dysfunction.20
Overall, thesafetyprofileobservedforeachChild-Pughscore
wasconsistentwiththeunderlyingdiseasestateandwiththepro-
file previously demonstrated for single-agent ramucirumab.21
Discussion
ThisanalysisofREACH11provides important insights intothere-
lationship of Child-Pugh score and the efficacy and safety of
ramucirumabtreatment inpatientswithadvancedHCC.Toour
knowledge, this is themost comprehensiveanalysisof the rela-
tionshipbetweenChild-Pughscoreandtheresults fromaphase
3 study in patients undergoing second-lineHCC treatment.
Analyses suggest that Child-Pugh class may still be prog-
nostic for survival in the second-line setting. In HCC studies
with sorafenib, theprognosis ofpatientswithChild-Pughclass
BHCC comparedwith thosewith class AHCC isworse,20,22,23
although analyses by Child-Pugh score are not commonly re-
ported. InREACH,Child-Pugh scores appeared tobeprognos-
tic in patients undergoing second-line HCC treatment, with a
shorter survival observed inpatientswithprogressivelyhigher
Child-Pugh scores on both treatment arms (Figure 1). It is no-
table that themedianOS in the placebo armof patientswith a
Child-Pugh of 6 (4.76months) was substantially shorter than
that of patientswith a Child-Pugh score of 5 (9.72months), as
historically the prognosis of patients with Child-Pugh class A
liver disease (ie, Child-Pugh5 and6 scores) have been consid-
ered to be similar.24 However, there are limited data on out-
comesas they relate toChild-Pugh score forpatientswithHCC
undergoingsecond-line treatmentafter sorafenib, and it is con-
ceivable that differences in the prognosis of Child-Pugh 5dis-
ease andChild-Pugh6disease aremore prominent in the sec-
ond-line compared with first-line settings. Whether an
alternative to the Child-Pugh score to classify patients’ liver
function based on objective measures of serum albumin and
bilirubin will better characterize prognosis in HCC is still un-
known; a recent analyses of theREACHsurvival results by se-
rum albumin and bilirubin grade defined 3 patient popula-
tions with different prognoses.25
In assessing treatment effect, a trend for a ramucirumab
survival benefit was only observed in the unselected patient
population with a Child-Pugh score of 5; no survival benefit
was observed in unselected patient populationswith a Child-
Pugh score of 6 or 7 and 8. Treatment arm imbalances are un-
likely to be the reason for the differential treatment effect by
Child-Pugh score because baseline characteristics were gen-
erally well balanced in each group. One possibility is that the
more severe liver dysfunction, as classified by Child-Pugh
score, negatively affects the ability of ramucirumab to pro-
duce a survival benefit in patients with advanced HCC. This
hypothesis would be consistent with the observed PFS ben-
efit in patients with a Child-Pugh 5 score; survival in patients
with higher Child-Pugh scores would be less likely improved
by tumor control. Similar to the REACH11 analyses presented
here,wealsonote that recent results of regorafenib as second-
line treatment of HCC also appear to favor a better survival in
patientswithaChild-Pughscoreof5comparedwith thosewith
aChild-Pugh6 score.12 Confounding of the survival endpoint
by severe liver dysfunction in HCC trials has been proposed
by others,26 and our analyses would support this hypothesis.
In selected patients with a baseline αFP level 400 ng/mL
ormore, an improvement inOSwas observed inpatientswith
Child-Pugh class A disease (Figure 2). No OS benefit was ob-
served in any Child-Pugh subgroup with baseline αFP levels
less than400ng/mL.These results are consistentwith theob-
servedsurvivalbenefit in the ITTpopulationwithbaselineαFP
levels either 400 ng/mL or more or less than 400 ng/mL re-
ported previously.11 No consistently predictive cancer bio-
markers are currently used to guide patient selection for sys-
temic antiangiogenesis treatments. Asdescribedpreviously,11
mountingevidence suggests that in aparticular subclassofpa-
tients with HCCwho have elevated αFP levels and poor prog-
nosis, intratumoral conditions may exist that enhance sensi-
tivity toVEGFR-2 inhibition.Alternatively, therecouldbeother
underlyingbaseline characteristics or posttreatmentmanage-
ment factors that contribute to the treatment benefit.Wenote
therewasanonsignificant trend forOSbenefit inpatientswith
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Child-Pugh 7 and 8 scores and αFP levels 400 ng/mL ormore
and that the absolute difference in median OS was modest.
However, in unselected patients with Child-Pugh scores of 7
and 8, the disease control rate was significantly higher for
ramucirumab. To our knowledge, this is the first report on ef-
ficacy for any systemic treatment compared with placebo in
patients with Child-Pugh class B liver function. Reasons why
PFS and response do not predict survival benefit in patients
with baseline αFP levels less than 400 ng/mL, for whom un-
derlying liver disease, cirrhosis, and other unknown factors
rather than HCC may lead to death, have been discussed
previously.11 Others have also recently reported a poor corre-
lation of PFS and OS in patients with HCC.27
Regardless of Child-Pugh score, the ramucirumab safety
profilewas generally consideredmanageable in patientswith
advanced HCC. In patients with Child-Pugh scores of 5 or 6,
hypertensionwas theonly grade3orhigherTEAEand/orAESI
higher in the ramucirumab vs placebo arm (observed in ≥10%
of patients in the ramucirumab arm and higher than placebo
[>5%difference]). This findingwas similar to thatwith single-
agent ramucirumab in the gastric or gastroesophageal junc-
tion adenocarcinomaphase III trial (REGARD),21 inwhich 1 of
only 2 grade 3 or higher events more common in the ramu-
cirumab arm than in the placebo armwas also hypertension.
InpatientswithChild-Pugh7and8 scores, liver injury, includ-
ing hepatic encephalopathy, and astheniawere the grade 3 or
higherTEAEsorAESIshigher for ramucirumabvsplaceboarms
(observed in ≥10% of patients on the ramucirumab arm and
higher than placebo [>5% difference]). The higher frequency
of liver injury and/or failure and bleeding AESIs in the Child-
Pugh 7 and 8 subgroup compared with the Child-Pugh 5 or 6
subgroups, regardlessof treatmentarm, isconsistentwithother
reports of an increased incidence of adverse events related to
liver cirrhosis in patients with higher Child-Pugh B scores
(Child-Pugh8and9).28Hence, thedifferences in themostcom-
mon TEAEs between the Child-Pugh 5 or 6 and Child-Pugh 7
and8subgroups are likely related to themore severe liverdys-
function and cirrhosis in patients with higher Child-Pugh
scores. Hepatic encephalopathy is an adverse event that is
largelyunique toapopulationwithend-stage liverdisease, and
the patientswith Child-Pugh 7 and 8 scoresmay have been at
higher risk for this event compared with patients with lower
Child-Pugh scores. A retrospective analysis of prior Child-
Pugh class B studies also reported encephalopathy as occur-
ring more frequently in patients with Child-Pugh class B dis-
ease comparedwith patients with Child-Pugh class A disease
treated with sorafenib.29 The mechanism for how ramu-
cirumabmight increase the risk of hepatic encephalopathy is
unknown. Notably, a clear increase in the incidence of many
other liver injury and/or failure eventswasnot observed. Cur-
rently, ramucirumab is recommended in approved indica-
tions (gastric or gastroesophageal junction adenocarcinoma,
non–small-cell lung cancer, and colorectal cancer) to be used
withcaution inpatientswithChild-PughclassB (orworse) liver
dysfunction.30
Conclusions
This exploratory analysis ofREACH11 demonstrates that inun-
selected patientswith a Child-Pugh score of 5, a trend for sur-
vival benefit from ramucirumab treatmentwas observed, but
no clear survival benefitwas observed in patientswithhigher
Child-Pugh scores. Regardless of Child-Pugh score, a poten-
tial ramucirumabsurvivalbenefitwasobserved inpatientswith
abaselineαFP level of 400ng/mLormore, supporting theuse
of baseline αFP as a method to identify those patients most
likely tobenefit fromramucirumab.Ramucirumabhadaman-
ageablesafetyprofile regardlessofChild-Pughscore.Therecon-
tinues tobehighunmetneed for aneffective treatment for pa-
tients with advanced HCC, and further investigation of the
efficacy and safety of ramucirumab in patients with HCC and
elevated baseline αFPwill be evaluated in an ongoing phase 3
trial (REACH-2; clinicaltrials.gov NCT02435433).
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